Company / R&D Expense
AbCellera Biologics Inc. R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$186.8M
FY2025
5-year range
$10.1M / $186.8M
FY2021-FY2025
Trend
+11.7%
vs FY2024
Sector context
#85 of 210
Health Care
What the data says
At $187M, AbCellera Biologics Inc.'s r&d expense ranks #85 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 7 years, ranging from $10M in FY2021 to $187M in FY2025.
Based on SEC 10-K filings.
$187M in FY2025 with a 5-year CAGR of +44.8%.
Improved from $176M to $187M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +85.2%
- 5-Year CAGR
- +44.8%
- 10-Year CAGR
- -
Sector benchmark
#85 of 210 in Health CareTop 40% of 210This company $186.8M Sector average $644.0M
▼
-71.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +44.8%, indicating consistent growth.
- In FY2025, r&d expense increased 11.7% year-over-year.
- Ranks #85 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $186.8M | +11.7% |
| FY2024 | $167.3M | -4.8% |
| FY2023 | $175.7M | +497.6% |
| FY2022 | $29.4M | +190.6% |
| FY2021 | $10.1M | -65.6% |
| FY2020 | $29.4M | +190.6% |
| FY2019 | $10.1M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026